Agios Pharmaceuticals Stock News

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest

CAMBRIDGE, Mass., July 16, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

Morgan Stanley decreased its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 20.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 122,38

Technically speaking, the U.S. benchmarks have registered a mid-July market whipsaw, writes Michael Ashbaugh, pressured at least briefly amid the month’s...

(Bloomberg) -- Seventeen months into her stint at the top of Agios Pharmaceuticals Inc., Jackie Fouse knows things could have gone better for investors.Shares of the drug developer have languished sin

The painful blood disorder, which mostly affects Black people, is just one of thousands of rare diseases that could be cured by Beam Therapeutics' revolutionary gene editing technology.

Technically speaking, the major U.S. benchmarks are off to a constructive July start despite persistently uneven price action, writes Michael Ashbaugh.

Guggenheim Capital LLC trimmed its position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 16.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities

Today we will run through one way of estimating the intrinsic value of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV) ADC...

Technically speaking, the major U.S. benchmarks are poised to conclude June against an increasingly uneven, but still generally bullish, bigger-picture...

Technically speaking, the U.S. benchmarks’ bigger-picture backdrop remains bullish, on balance, despite increasingly uneven market price action, writes...

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Agios Pharmaceuticals (NASDAQ:AGIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. They currently h